VIVUS (VVUS) Cuts Qsymia Price by About 70%; Arena (ARNA) on Watch

March 4, 2013 10:08 AM EST Send to a Friend
Get Alerts VVUS Hot Sheet
Price: $2.98 +6.81%

Rating Summary:
    5 Buy, 7 Hold, 5 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 7 | Down: 23 | New: 27
Trade VVUS Now!
Join SI Premium – FREE
VIVUS, Inc. (Nasdaq: VVUS) may be lowering the price of its Qsymia just months after commercialization began.

According to Bloomberg Industries' Andrew Berens, VIVUS will start offering 30-days of medium-dose Qsymia for maximum out-of-pocket cost of $75.

Along with the current 14-day free trial program on low-dose Qsymia, patients will be able to get six weeks of therapy for $75, which is 70 percent below the list price.

Action by VIVUS might also pose risks for Arena Pharmaceutical (Nasdaq: ARNA) and Eisai's Belviq, a competitor to Qsymia. Belviq will have a wholesale cost of about $200 for four weeks of therapy. Berens notes that pharmacy mark-up will lead to higher retail costs for Belviq.

Last Friday, Arena said Belviq hasn’t received final scheduling designation from DEA required before introduction.

Shares of VIVUS are down about 2 percent Monday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA, Trader Talk

Add Your Comment